Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 9/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993104 | 0.86 | HDAC6 (0.53) | HDAC1HDAC8HDAC6PLA2G4ALTB4R | |
| SCHEMBL4253982 | 0.82 | HDAC1 (0.48) | HDAC1HDAC8HDAC6PLA2G4AHDAC3 | |
| SCHEMBL4251089 | 0.81 | PLA2G4A (0.56) | HDAC1HDAC8HDAC6PLA2G4A | |
| SCHEMBL4249517 | 0.76 | HASPIN (0.39) | HASPIN | |
| SCHEMBL4255197 | 0.76 | HASPIN (0.47) | HDAC1HDAC8HDAC6MEN1KMT2A | |
| SCHEMBL4254269 | 0.76 | HASPIN (0.56) | HDAC1HDAC8HDAC6MEN1KMT2A | |
| SCHEMBL24872812 | 0.75 | HTR6 (0.52) | HDAC1HDAC8HDAC6PLA2G4AMEN1 | |
| SCHEMBL4251752 | 0.72 | CDK2 (0.42) | HDAC1HDAC8HDAC6PLA2G4ALTB4R | |
| SCHEMBL15687602 | 0.70 | HASPIN (0.50) | HASPIN | |
| SCHEMBL13948947 | 0.69 | SLC22A12 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC8, HDAC3 | HDAC1 1/4885HDAC8 2/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.